Vivos Therapeutics Inc (NASDAQ:VVOS)’s traded shares stood at 77041.0 during the last session, with the company’s beta value hitting 7.90. At the close of trading, the stock’s price was $4.83, to imply an increase of 3.87% or $0.18 in intraday trading. The VVOS share’s 52-week high remains $48.79, putting it -910.14% down since that peak but still an impressive 43.48% since price per share fell to its 52-week low of $2.73. The company has a valuation of $6.42M, with an average of 64819.99999999999 shares in intraday trading volume over the past 10 days and average of 117.91K shares over the past 3 months.
Vivos Therapeutics Inc (NASDAQ:VVOS) trade information
After registering a 3.87% upside in the last session, Vivos Therapeutics Inc (VVOS) has traded red over the past five days. The stock hit a weekly high of 5.24, jumping 3.87% in its intraday price action. The 5-day price performance for the stock is -1.63%, and -7.12% over 30 days. With these gigs, the year-to-date price performance is -61.17%. Short interest in Vivos Therapeutics Inc (NASDAQ:VVOS) saw shorts transact 26180.0 shares and set a 0.34 days time to cover.
Vivos Therapeutics Inc (VVOS) estimates and forecasts
Revenue is forecast to grow 62.00% this quarter before jumping 22.30% for the next one. The rating firms project that company’s revenue will shrink -12.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is $3.41 million. Meanwhile, for the quarter ending Mar 2024, a total of 2 analyst(s) estimate revenue growth to $3.61 million.Earnings reports from the last fiscal year show that sales brought in $3.95 million and $3.86 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -13.70% before dropping -6.40% in the following quarter.
VVOS Dividends
Vivos Therapeutics Inc has its next earnings report out between March 28 and April 01. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Vivos Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Vivos Therapeutics Inc (NASDAQ:VVOS)’s Major holders
Vivos Therapeutics Inc insiders hold 15.22% of total outstanding shares, with institutional holders owning 19.21% of the shares at 22.66% float percentage. In total, 19.21% institutions holds shares in the company, led by Strategic Wealth Investment Group, LLC. As of Jun 29, 2023, the company held over 3.22 million shares (or 10.76% of shares), all amounting to roughly $1.64 million.
The next major institution holding the largest number of shares is Vanguard Group Inc with 0.71 million shares, or about 2.39% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $0.36 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Vivos Therapeutics Inc (VVOS) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 0.43 million shares. This is just over 1.42% of the total shares, with a market valuation of $0.22 million. Data from the same date shows that the other fund manager holds a little less at 0.26 million, or 0.88% of the shares, all valued at about 0.13 million.
